Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction

Anne Hedegaard; Rasmus Sejersten Ripa; Julia S Johansen; Erik Jørgensen; Jens Kastrup

doi:10.3109/00365510903518191

Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction

Anne Hedegaard, Rasmus Sejersten Ripa, Julia S Johansen, Erik Jørgensen, Jens Kastrup

23 Citations (Scopus)

Abstract

Background: Plasma YKL-40 is increased early in patients with ST-elevation myocardial infarction (STEMI). It is not known whether plasma YKL-40 is related to infarct size and recovery of ventricular function after primary percutaneous coronary intervention (PCI) of STEMI and whether granulocyte colony-stimulating factor (G-CSF) therapy influence plasma YKL-40 concentration. Materials and methods: A total of 72 patients (age: 56 ± 9 years (mean ± SD), 56 men and 16 women) with STEMI treated with PCI were included in a double-blind, randomized, placebo-controlled trial with subcutaneous G-CSF or placebo injections from day 1 to 7 after the STEMI. Plasma YKL-40, high-sensitivity C-reactive protein (hs-CRP) and CK-MB concentrations were measured at baseline and during the first month. Infarct size and left ventricular ejection fraction (LVEF) were measured by magnetic resonance imaging at baseline and after 6 months. Results: Baseline plasma YKL-40 was increased (median 92 μg/L) compared to healthy subjects (median 34 μg/L, p <0.001). In the placebo group hs-CRP and YKL-40 correlated at baseline (p 0.04) and day 3 (p 0.01), but not at day 7 and 30. Moreover, YKL-40 correlated negatively to LVEF recovery (p 0.04) but not infarct size. G-CSF injections increased YKL-40 compared to placebo (p <0.001), but were not associated with infarct size or LVEF recovery. Conclusion: Plasma YKL-40 was significantly increased in STEMI patients at admission and G-CSF treatment caused a further increase in YKL-40. Plasma YKL-40 may be an indirect marker of LVEF recovery, independent of hs-CRP, and higher plasma YKL-40 indicates a lower recovery.

Original language	English
Journal	Scandinavian Journal of Clinical & Laboratory Investigation
Volume	70
Issue number	2
Pages (from-to)	80-6
Number of pages	7
ISSN	0036-5513
DOIs	https://doi.org/10.3109/00365510903518191
Publication status	Published - Apr 2010
Externally published	Yes

Keywords

Adipokines
Aged
Biological Markers
Blood
C-Reactive Protein
Creatine Kinase, MB Form
Double-Blind Method
Female
Glycoproteins
Granulocyte Colony-Stimulating Factor
Humans
Inflammation
Lectins
Male
Middle Aged
Myocardial Infarction
Stroke Volume
Treatment Outcome
Ventricular Dysfunction, Left

Access to Document

10.3109/00365510903518191

Cite this

@article{380e9497fcd347ccbabb9d04beebadde,

title = "Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction",

abstract = "Background: Plasma YKL-40 is increased early in patients with ST-elevation myocardial infarction (STEMI). It is not known whether plasma YKL-40 is related to infarct size and recovery of ventricular function after primary percutaneous coronary intervention (PCI) of STEMI and whether granulocyte colony-stimulating factor (G-CSF) therapy influence plasma YKL-40 concentration. Materials and methods: A total of 72 patients (age: 56 ± 9 years (mean ± SD), 56 men and 16 women) with STEMI treated with PCI were included in a double-blind, randomized, placebo-controlled trial with subcutaneous G-CSF or placebo injections from day 1 to 7 after the STEMI. Plasma YKL-40, high-sensitivity C-reactive protein (hs-CRP) and CK-MB concentrations were measured at baseline and during the first month. Infarct size and left ventricular ejection fraction (LVEF) were measured by magnetic resonance imaging at baseline and after 6 months. Results: Baseline plasma YKL-40 was increased (median 92 μg/L) compared to healthy subjects (median 34 μg/L, p <0.001). In the placebo group hs-CRP and YKL-40 correlated at baseline (p 0.04) and day 3 (p 0.01), but not at day 7 and 30. Moreover, YKL-40 correlated negatively to LVEF recovery (p 0.04) but not infarct size. G-CSF injections increased YKL-40 compared to placebo (p <0.001), but were not associated with infarct size or LVEF recovery. Conclusion: Plasma YKL-40 was significantly increased in STEMI patients at admission and G-CSF treatment caused a further increase in YKL-40. Plasma YKL-40 may be an indirect marker of LVEF recovery, independent of hs-CRP, and higher plasma YKL-40 indicates a lower recovery.",

keywords = "Adipokines, Aged, Biological Markers, Blood, C-Reactive Protein, Creatine Kinase, MB Form, Double-Blind Method, Female, Glycoproteins, Granulocyte Colony-Stimulating Factor, Humans, Inflammation, Lectins, Male, Middle Aged, Myocardial Infarction, Stroke Volume, Treatment Outcome, Ventricular Dysfunction, Left",

author = "Anne Hedegaard and Ripa, {Rasmus Sejersten} and Johansen, {Julia S} and Erik J{\o}rgensen and Jens Kastrup",

year = "2010",

month = apr,

doi = "10.3109/00365510903518191",

language = "English",

volume = "70",

pages = "80--6",

journal = "Scandinavian Journal of Clinical & Laboratory Investigation",

issn = "0036-5513",

publisher = "Taylor & Francis",

number = "2",

}

TY - JOUR

T1 - Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction

AU - Hedegaard, Anne

AU - Ripa, Rasmus Sejersten

AU - Johansen, Julia S

AU - Jørgensen, Erik

AU - Kastrup, Jens

PY - 2010/4

Y1 - 2010/4

N2 - Background: Plasma YKL-40 is increased early in patients with ST-elevation myocardial infarction (STEMI). It is not known whether plasma YKL-40 is related to infarct size and recovery of ventricular function after primary percutaneous coronary intervention (PCI) of STEMI and whether granulocyte colony-stimulating factor (G-CSF) therapy influence plasma YKL-40 concentration. Materials and methods: A total of 72 patients (age: 56 ± 9 years (mean ± SD), 56 men and 16 women) with STEMI treated with PCI were included in a double-blind, randomized, placebo-controlled trial with subcutaneous G-CSF or placebo injections from day 1 to 7 after the STEMI. Plasma YKL-40, high-sensitivity C-reactive protein (hs-CRP) and CK-MB concentrations were measured at baseline and during the first month. Infarct size and left ventricular ejection fraction (LVEF) were measured by magnetic resonance imaging at baseline and after 6 months. Results: Baseline plasma YKL-40 was increased (median 92 μg/L) compared to healthy subjects (median 34 μg/L, p <0.001). In the placebo group hs-CRP and YKL-40 correlated at baseline (p 0.04) and day 3 (p 0.01), but not at day 7 and 30. Moreover, YKL-40 correlated negatively to LVEF recovery (p 0.04) but not infarct size. G-CSF injections increased YKL-40 compared to placebo (p <0.001), but were not associated with infarct size or LVEF recovery. Conclusion: Plasma YKL-40 was significantly increased in STEMI patients at admission and G-CSF treatment caused a further increase in YKL-40. Plasma YKL-40 may be an indirect marker of LVEF recovery, independent of hs-CRP, and higher plasma YKL-40 indicates a lower recovery.

AB - Background: Plasma YKL-40 is increased early in patients with ST-elevation myocardial infarction (STEMI). It is not known whether plasma YKL-40 is related to infarct size and recovery of ventricular function after primary percutaneous coronary intervention (PCI) of STEMI and whether granulocyte colony-stimulating factor (G-CSF) therapy influence plasma YKL-40 concentration. Materials and methods: A total of 72 patients (age: 56 ± 9 years (mean ± SD), 56 men and 16 women) with STEMI treated with PCI were included in a double-blind, randomized, placebo-controlled trial with subcutaneous G-CSF or placebo injections from day 1 to 7 after the STEMI. Plasma YKL-40, high-sensitivity C-reactive protein (hs-CRP) and CK-MB concentrations were measured at baseline and during the first month. Infarct size and left ventricular ejection fraction (LVEF) were measured by magnetic resonance imaging at baseline and after 6 months. Results: Baseline plasma YKL-40 was increased (median 92 μg/L) compared to healthy subjects (median 34 μg/L, p <0.001). In the placebo group hs-CRP and YKL-40 correlated at baseline (p 0.04) and day 3 (p 0.01), but not at day 7 and 30. Moreover, YKL-40 correlated negatively to LVEF recovery (p 0.04) but not infarct size. G-CSF injections increased YKL-40 compared to placebo (p <0.001), but were not associated with infarct size or LVEF recovery. Conclusion: Plasma YKL-40 was significantly increased in STEMI patients at admission and G-CSF treatment caused a further increase in YKL-40. Plasma YKL-40 may be an indirect marker of LVEF recovery, independent of hs-CRP, and higher plasma YKL-40 indicates a lower recovery.

KW - Adipokines

KW - Aged

KW - Biological Markers

KW - Blood

KW - C-Reactive Protein

KW - Creatine Kinase, MB Form

KW - Double-Blind Method

KW - Female

KW - Glycoproteins

KW - Granulocyte Colony-Stimulating Factor

KW - Humans

KW - Inflammation

KW - Lectins

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Stroke Volume

KW - Treatment Outcome

KW - Ventricular Dysfunction, Left

U2 - 10.3109/00365510903518191

DO - 10.3109/00365510903518191

M3 - Journal article

C2 - 20102300

SN - 0036-5513

VL - 70

SP - 80

EP - 86

JO - Scandinavian Journal of Clinical & Laboratory Investigation

JF - Scandinavian Journal of Clinical & Laboratory Investigation

IS - 2

ER -

Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction

Abstract

Keywords

Access to Document

Fingerprint

Cite this